
Eledon Pharmaceuticals, Inc. / Fundamentals
Income statement
- Net revenue
€165.42K - Cost of goods sold
€0.00 - Gross profit
€165.42K - SG&A expenses
€16.93M - R&D expenses
€58.81M - EBITDA
-€75.59M - D&A
€143.88K - EBIT
-€75.57M - Interest expenses
€0.00 - EBT
€12.99M - Tax expenses
-€371.33K - Net income
€12.62M
Cash flow statement
- Net deferred tax
€371.33K - Non-cash items
-€53.89M - Changes in working capital
-€4.26M - Operating cash flow
-€55.59M - Capex
€0.00 - Other investing cash flow
€0.00 - Net investing cash flow
-€35.61M - Total cash dividends paid
€0.00 - Issuance of common stock
€73.43M - Debt repayment
€0.00 - Other financing cash flow
€284.31K - Net financing cash flow
€73.72M - Foreign exchange effects
€0.00 - Net change in cash
-€17.49M - Cash at end of period
€4.95M - Free cash flow
-€55.59M
Balance sheet
- Cash and cash equivalents
€4.95M - Cash and short-term investments
€92.68M - Total receivables
€607.39K - Inventory
€0.00 - Other current assets
€2.70M - Total current assets
€95.98M - Property, plant & equipment
€665.98K - Goodwill
€0.00 - Intangible assets
€27.90M - Long-term investments
€0.00 - Other non-current assets
€298.10K - Total non-current assets
€28.87M - Total assets
€124.85M - Accounts payable
€5.02M - Short-term debt
€289.48K - Other current liabilities
€6.51M - Total current liabilities
€11.82M - Long-term debt
€402.34K - Deferred tax liabilities
€1.88M - Other non-current liabilities
€67.38M - Total non-current liabilities
€69.66M - Total liabilities
€81.48M - Common stock
€51.69K - Retained earnings
-€321.61M - Other equity
-€41.35K - Total equity
€43.37M - Total liabilities and shareholders' equity
€124.85M
Company information
- Market capitalization
€137.40M - Employees
31 - Enterprise Value
€172.03M
Company ratios
- Gross margin
-
100.0% Much better than peer group: -224.6% - EBITDA margin
-
-45,695.8% Much worse than peer group: -4,399.8% - EBIT margin
-
-45,682.8% Much worse than peer group: -4,424.5% - EBT margin
-
7,851.0% Much better than peer group: -4,255.8% - Net margin
-
7,626.6% Much better than peer group: -4,244.3% - ROE
-
29.1% Much better than peer group: -44.6% - ROA
-
10.1% Much better than peer group: -45.9% - Asset turnover
-
0.1% Worse than peer group: 9.0% - FCF margin
-
-33,608.9% Much worse than peer group: -3,505.9% - FCF yield
-40.5% - Efficiency ratio
45,795.8% - Net sales per employee
-
€5.34K - Net income per employee
-
€406.96K